{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:00:14Z","timestamp":1792144814398,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10620-026-09995-3","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:47:20Z","timestamp":1780555640000},"page":"4831-4841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"71","author":[{"given":"Navneet","family":"Natt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Shafrir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila R.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krugliak Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"9995_CR1","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1\u2013s106. https:\/\/doi.org\/10.1136\/gutjnl-2019-318484.","journal-title":"Gut"},{"key":"9995_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","volume":"13","author":"CRH Hedin","year":"2019","unstructured":"Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, Gonz\u00e1lez-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis 2019;13:541\u2013554. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy191.","journal-title":"J Crohns Colitis"},{"key":"9995_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D\u2019Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 2024;9:415\u2013427. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9995_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","volume":"16","author":"M Fumery","year":"2018","unstructured":"Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol 2018;16:343-356.e3. https:\/\/doi.org\/10.1016\/j.cgh.2017.06.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9995_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2025.101981","volume":"77","author":"V Solitano","year":"2025","unstructured":"Solitano V, Han\u017eel J, Estevinho MM, Sedano R, Massimino L, Ungaro F, Jairath V. Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution? Best Pract Res Clin Gastroenterol 2025;77:101981. https:\/\/doi.org\/10.1016\/j.bpg.2025.101981.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"9995_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ueg2.12366","volume":"11","author":"F Magro","year":"2023","unstructured":"Magro F, Moreira PL, Catalano G, Alves C, Roseira J, Estevinho MM, Silva I, Dignass A, Peyrin-Biroulet L, Danese S, Jairath V, Dias CC, Santiago M. Has the therapeutical ceiling been reached in Crohn\u2019s disease randomized controlled trials? A systematic review and meta-analysis. United European Gastroenterol J 2023;11:202\u2013217. https:\/\/doi.org\/10.1002\/ueg2.12366.","journal-title":"United European Gastroenterol J"},{"key":"9995_CR7","doi-asserted-by":"publisher","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","volume":"5","author":"R Panaccione","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY, Vermeire S, Danese S, Higgins PDR, Kwon CS, Zhou W, Ilo D, Sharma D, Sanchez Gonzalez Y, Wang ST. Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohns Colitis 360 2023;5:otad009. https:\/\/doi.org\/10.1093\/crocol\/otad009.","journal-title":"Crohns Colitis 360"},{"key":"9995_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/apt.18110","volume":"60","author":"M Attauabi","year":"2024","unstructured":"Attauabi M, Steenholdt C, Poulsen A, Gubatan J, Burisch J, Nielsen OH, Seidelin JB. Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease. Aliment Pharmacol Ther 2024;60:124\u2013143. https:\/\/doi.org\/10.1111\/apt.18110.","journal-title":"Aliment Pharmacol Ther"},{"key":"9995_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/apt.70295","volume":"62","author":"M Shehab","year":"2025","unstructured":"Shehab M, Alrashed F, Alrashidi A, Hassan A, Ma C, Narula N, Jairath V, Regueiro M, Bessissow T. Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn\u2019s Disease. Aliment Pharmacol Ther 2025;62:472\u2013482. https:\/\/doi.org\/10.1111\/apt.70295.","journal-title":"Aliment Pharmacol Ther"},{"key":"9995_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","volume":"69","author":"Y Miyatani","year":"2024","unstructured":"Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn\u2019s Disease. Dig Dis Sci 2024;69:355\u2013359. https:\/\/doi.org\/10.1007\/s10620-023-08182-y.","journal-title":"Dig Dis Sci"},{"key":"9995_CR11","doi-asserted-by":"crossref","unstructured":"Fear EN, McDonald BD, McMillan RH, Fine ZD, McDermott A, Kellar A, Rubin DT (2026) Dual-targeted therapy with risankizumab and upadacitinib is clinically and biochemically effective in medically complex Crohn\u2019s disease. CC360. Accepted for publication May 2026.","DOI":"10.1093\/crocol\/otag049"},{"key":"9995_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","volume":"405","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Allegretti JR, Pan\u00e9s J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet 2025;405:33\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(24)01927-5.","journal-title":"Lancet"},{"key":"9995_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","volume":"169","author":"A Hart","year":"2025","unstructured":"Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D\u2019Haens G. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn\u2019s Disease: Results From the Phase 3 GRAVITI Study. Gastroenterology 2025;169:308\u2013325. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.033.","journal-title":"Gastroenterology"},{"key":"9995_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2468-1253(25)00322-X","volume":"11","author":"M Long","year":"2026","unstructured":"Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, J\u00f6rgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2026;11:284\u2013298. https:\/\/doi.org\/10.1016\/S2468-1253(25)00322-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9995_CR15","doi-asserted-by":"publisher","first-page":"2050313X2513521","DOI":"10.1177\/2050313X251352160","volume":"13","author":"S Antolini","year":"2025","unstructured":"Antolini S, Scagliosi G, Veliaj O, Carletto A, Fracassi E, Gisondi P. A successful combination of upadacitinib and guselkumab in refractory psoriasis and psoriatic arthritis: A case report. SAGE Open Med Case Rep 2025;13:2050313X251352160. https:\/\/doi.org\/10.1177\/2050313X251352160.","journal-title":"SAGE Open Med Case Rep"},{"key":"9995_CR16","doi-asserted-by":"crossref","unstructured":"Sands BE, D\u2019Haens G, Dotan I, Terry NA, Walker M, Bundy V, Perry H, Vetter M, Kobayashi T, Schreiber S, Jairath V. Efficacy And Safety Of The First Co-Antibody Therapy, Jnj-78934804, In Patients With Moderately To Severely Active Crohn\u2019s Disease Refractory To Systemic Therapies. (Abstract 979f) Presented at Digestive Disease Week (DDW) May 2\u20135, 2026.","DOI":"10.1016\/S0016-5107(26)06683-6"},{"key":"9995_CR17","doi-asserted-by":"crossref","unstructured":"Abrey MT, Sands BE, Vermeire S, Panacionne R, Moore G, Atreya R, Lynch J, Marko MG, Jung ES, Alexandrova S, Perry H, Vetter M, Panes J. Efficacy And Safety Of The First Co-Antibody Therapy, Jnj-78934804, In Patients With Moderately To Severely Active Ulcerative Colitis Refractory To Systemic Therapies. (Abstract 1058d) Presented at Digestive Disease Week (DDW) May 2\u20135, 2026.","DOI":"10.1016\/S0016-5107(26)06687-3"},{"key":"9995_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5217\/ir.2024.00174","volume":"23","author":"R Gilmore","year":"2025","unstructured":"Gilmore R, Murali A, Etchegaray A, Swe E, An YK, Begun J. Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn\u2019s disease. Intest Res 2025;23:475\u2013482. https:\/\/doi.org\/10.5217\/ir.2024.00174.","journal-title":"Intest Res"},{"key":"9995_CR19","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/JIR.S511309","volume":"18","author":"MJ Meng","year":"2025","unstructured":"Meng MJ, Kuo CJ, Lai MW, Chiu CT, Su MY, Chang ML. Le PH (2025) Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan. J Inflamm Res. 2025;18:2733\u20132742. https:\/\/doi.org\/10.2147\/JIR.S511309.","journal-title":"J Inflamm Res."},{"key":"9995_CR20","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022;20:e361\u2013e379. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9995_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fphar.2019.00212","volume":"10","author":"T P\u00e9rez-Jeldres","year":"2019","unstructured":"P\u00e9rez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol 2019;10:212. https:\/\/doi.org\/10.3389\/fphar.2019.00212","journal-title":"Front Pharmacol"},{"key":"9995_CR22","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","volume":"61","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Szekanecz Z, McGonagle D, Maksymowych WP, Pfeil A, Lippe R, Song IH, Lertratanakul A, Sornasse T, Biljan A, Deodhar A. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford) 2022;61:1783\u20131794. https:\/\/doi.org\/10.1093\/rheumatology\/keab740.","journal-title":"Rheumatology (Oxford)"},{"key":"9995_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1126\u20131136. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","journal-title":"Lancet"},{"key":"9995_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-024-03380-z","volume":"26","author":"KM Lee","year":"2024","unstructured":"Lee KM, Lupancu T, Chang L, Manthey CL, Zeeman M, Fourie AM, Hamilton JA. The mode of action of IL-23 in experimental inflammatory arthritic pain and disease. Arthritis Res Ther 2024;26:148. https:\/\/doi.org\/10.1186\/s13075-024-03380-z.","journal-title":"Arthritis Res Ther"},{"key":"9995_CR25","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, H\u00e9buterne X, D\u2019Haens G, Nakase H, Pan\u00e9s J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022;399:2113\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet"},{"key":"9995_CR26","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, Reinisch W, Louis E, Chen M, Nakase H, Begun J, Boland BS, Phillips C, Mohamed MF, Liu J, Geng Z, Feng T, Dubcenco E, Colombel JF. Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease. N Engl J Med 2023;388:1966\u20131980. https:\/\/doi.org\/10.1056\/NEJMoa2212728.","journal-title":"N Engl J Med"},{"key":"9995_CR27","doi-asserted-by":"publisher","first-page":"00668","DOI":"10.1016\/j.cgh.2025.07.042","volume":"S1542\u20133565","author":"AHY Ho","year":"2025","unstructured":"Ho AHY, Choi D, Mathew AJ, McDermott A, Fine Z, Fear E, Choi NK, Cohen RD, Dalal SR, Pekow J, Krugliak Cleveland N, Rubin DT. Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025;S1542\u20133565:00668\u201300678. https:\/\/doi.org\/10.1016\/j.cgh.2025.07.042.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09995-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09995-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09995-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:02:10Z","timestamp":1789048930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09995-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9995"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09995-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NN and AS have no relevant financial or non-financial interests to disclose. DC has served as a speaker bureau for Janssen Pharmaceuticals and as a consultant for Abbvie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Prometheus Laboratory, and Boehringer Ingelheim. SRD has served as a speaker bureau for Abbvie and as a consultant for Johnson & Johnson. NKC has served as a consultant for NeuroLogica (a subsidiary of Samsung Electronics), Johnson & Johnson Pharmaceuticals, GE Healthcare, Abbvie, and Sanofi. She is on the Board of Directors for the Intestinal Ultrasound Group of the United States and Canada (iUSCAN). RDC has served as a consultant for Abbvie, Eli Lilly, Genentech, Gilead Sciences, Johnson & Johnson, Pfizer, Takeda. DTR\u00a0has received grant support from Takeda, and has served as a consultant for Abbvie, Abivax SA, Altrubio, Athos Therapeutics, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co., Genentech (Roche) Inc., Gilead Sciences, Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Tr1X, Inc., Vedanta Biosciences, Ventyx and ZS Associates, Inc. He is also on the Board of Directors for Cornerstones Health (non-profit), iUSCAN (non-profit).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with ethical standards outlined by the institutional and national research committee and the 1964 Helsinki Declaration. Approval was received from the Institutional Review Board at the University of Chicago for the real-world prospective database as part of the IBD Catalyst Project.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}